Welcome to our dedicated page for Arcturus Therapeutics Holdings news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therapeutics Holdings stock.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), founded in 2013 and based in San Diego, California, is a pioneering RNA medicines company focused on developing novel therapeutics for rare diseases, particularly those with no adequate treatments. Specializing in RNA interference (RNAi) technologies, Arcturus is at the forefront of creating breakthrough treatments aimed at liver and respiratory diseases.
Arcturus operates primarily in the research and development sector, focusing on nucleic acid-based medical applications. Core technologies include its proprietary LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA), enabling a versatile range of RNA therapeutics. Its mRNA drug substance and product manufacturing expertise further position Arcturus as a leader in RNA-based solutions.
Key projects in Arcturus' pipeline include:
- LUNAR-OTC for treating ornithine transcarbamylase deficiency
- LUNAR-CF aimed at cystic fibrosis
- LUNAR-FLU and LUNAR-COV19 for influenza and COVID-19 vaccines respectively
Recently, Arcturus announced a collaborative research endeavor with PassPort Technologies Inc. (PPTI) to explore innovative mRNA formulations and transdermal delivery methods for vaccines and therapeutics. This partnership leverages ARCT’s LUNAR® platform and PPTI’s PassPort® transdermal technology, aiming to enhance the delivery and efficacy of RNA-based treatments.
Further cementing its competitive edge, Arcturus has developed Kostaive®, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine. Arcturus continues its global collaboration with CSL Seqirus for mRNA vaccines and maintains a joint venture in Japan, ARCALIS, to manufacture mRNA vaccines and therapeutics. The company’s extensive patent portfolio, covering over 400 patents across the U.S., Europe, Japan, China, and other countries, underscores its innovative prowess.
Financially, Arcturus maintains a solid growth trajectory, driven by its robust research initiatives and strategic alliances. For more detailed information, visit their official website at www.ArcturusRx.com, and connect via Twitter and LinkedIn.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has received approval for a Clinical Trial Application (CTA) from Singapore's Health Sciences Authority for two of its STARR™ mRNA vaccine candidates, ARCT-154 and ARCT-165. The upcoming Phase 1/2 trial aims to evaluate their efficacy as primary vaccinations and boosters against SARS-CoV-2 variants, including Delta. Funding for the trial is partly sourced from a secured grant. Preclinical studies show strong immune responses in non-human primates for these vaccine candidates, thus positioning Arcturus for significant developments in the vaccine market.
Arcturus Therapeutics (NASDAQ: ARCT) announced that its partner, Vinbiocare, has received approval from the Vietnam Ministry of Health for a Clinical Trial Application (CTA) to proceed with a Phase 1/2/3 clinical study of ARCT-154, targeting SARS-CoV-2 variants, including Delta. The trial will enroll up to 21,000 participants and assess safety, immunogenicity, and efficacy. If successful, Emergency Use Approval (EUA) is anticipated. Preclinical data shows ARCT-154 induced strong neutralizing antibody responses to variants of concern, particularly the Delta variant.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced a collaboration with Vinbiocare Biotechnology to establish a COVID-19 vaccine manufacturing facility in Vietnam. Vinbiocare will invest $40 million upfront and manage the technology transfer necessary for production, with a capacity of up to 200 million doses annually. Arcturus will grant an exclusive license for production in Vietnam, supplying proprietary technology for the manufacturing process. This partnership aims to enhance vaccine accessibility in Vietnam and other regions.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has received approval from the UK Health Research Authority to start a Phase 2 clinical study for ARCT-810, an mRNA-based treatment for Ornithine Transcarbamylase (OTC) deficiency. This study aims to assess safety, tolerability, and efficacy in up to 24 participants over 12 weeks. The trial builds on positive Phase 1 results, highlighting ARCT-810's potential to restore urea cycle function and mitigate neurological damage in OTC deficiency patients.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for Q2 2021 on August 9, 2021, after market close. A conference call will follow at 4:30 PM ET, where investors can discuss the results. The company specializes in mRNA medicines and vaccines aimed at infectious diseases and rare conditions affecting the liver and respiratory system. Arcturus utilizes advanced technologies like LUNAR® lipid-mediated delivery and STARR™ mRNA Technology, featuring a pipeline that includes candidates for SARS-CoV-2 and Influenza vaccines.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced participation in several upcoming investor and scientific conferences. Key events include the mRNA-Based Therapeutics Summit on July 13-14, 2021, and the Ladenburg Thalmann 2021 Healthcare Conference also on July 13, followed by the Cell-Mediated Therapies for Infectious Disease Summit on July 22, 2021. This highlights Arcturus' focus on advancing its mRNA vaccine programs for various diseases. More details and links can be found on their Investor Relations page.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a clinical-stage company specializing in messenger RNA therapies, has announced its participation in several upcoming conferences. These include the BIO Digital 2021 on June 10, 2nd Annual RNAi-Based Therapeutics Summit on June 17, SVB Leerink CybeRx Series: Vaccine Forum on June 21, and 2021 RNA Therapeutics Symposium on June 24. Arcturus focuses on infectious disease vaccines and treatments for rare liver and respiratory diseases, showcasing a diverse pipeline and extensive patent portfolio.
Primordial Genetics announced an exclusive license agreement with Arcturus Therapeutics Holdings Inc. (ARCT) for a novel RNA polymerase enzyme, aimed at enhancing the manufacturing of long, high-quality RNAs for therapeutic use. This collaboration is expected to significantly improve the efficiency and cost-effectiveness of mRNA production, which is vital for drug and vaccine development. Primordial's technology emphasizes innovative RNA manufacturing processes that could lead to advancements in pharmaceuticals, ultimately aiming to address pressing health needs.
Arcturus Therapeutics (Nasdaq: ARCT) reported Q1 2021 financial results, noting revenue of $2.1 million, down from $2.6 million year-over-year. The company incurred a net loss of $56.3 million, reflecting an increase in operating expenses to $59.8 million, driven by higher R&D costs for its ARCT-021 COVID-19 vaccine candidate. The Phase 2 trial for ARCT-021 has completed enrollment with promising interim immunogenicity data supporting plans for a Phase 3 study. Cash reserves are strong at $466.9 million, expected to cover operations for over two years.
Arcturus Therapeutics Holdings (Nasdaq: ARCT) will announce its Q1 2021 financial results on May 10, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET on the same day. The company focuses on mRNA medicines targeting infectious diseases and rare liver and respiratory diseases. Arcturus has a diverse pipeline including vaccines for SARS-CoV-2 and influenza, as well as programs for Ornithine Transcarbamylase Deficiency and Cystic Fibrosis.
FAQ
What is the current stock price of Arcturus Therapeutics Holdings (ARCT)?
What is the market cap of Arcturus Therapeutics Holdings (ARCT)?
What does Arcturus Therapeutics specialize in?
What are the core technologies of Arcturus Therapeutics?
What kind of diseases is Arcturus targeting with its therapies?
What recent collaborations has Arcturus entered into?
What is Kostaive®?
Who are Arcturus' major partners?
What is LUNAR-OTC?
How extensive is Arcturus' patent portfolio?
Where is Arcturus Therapeutics headquartered?
How can I get more information about Arcturus Therapeutics?
